DEF: Insmed's 2026 Proxy: Director Elections, Executive Pay, and Growth

Sentiment:

Definitive Proxy Statement 1 April 2026 4:01 PM

Insmed Incorporated announces its 2026 Annual Meeting of Shareholders to elect directors, conduct an advisory vote on 2025 executive compensation, and ratify its independent auditor, highlighting significant 2025 commercial and clinical advancements.

Capital raiseEnhanced the balance sheet through a public equity offering.Redeemed all outstanding 0.75% convertible senior notes due in 2028.

Better than expectedTotal Company revenues of $606.4 million in 2025, including a 19% year-over-year increase in global ARIKAYCE revenues.Successful launch of BRINSUPRI in the U.S. and approvals in the EU and UK.Positive topline results from the Phase 2b study of TPIP in PAH, meeting primary and secondary efficacy endpoints.Stock price increased by over 150% in 2025, significantly outperforming the Nasdaq Biotech Index.2022 PSUs vested due to Insmed's TSR ranking in the top decile of the peer group.

Summary

The 2026 Annual Meeting of Shareholders will be held virtually on May 13, 2026, at 9:00 a.m. Eastern Time, with a Record Date of March 6, 2026.
Shareholders will vote on the election of two Class II directors, an advisory vote on 2025 named executive officer (NEO) compensation, and the ratification of Ernst & Young LLP as the independent registered public accounting firm for 2026.
Total Company revenues reached $606.4 million in 2025, driven by a 19% year-over-year increase in global ARIKAYCE revenues.
BRINSUPRI (brensocatib) received U.S. approval in August 2025, EU approval in November 2025, and UK approval in February 2026 for non-cystic fibrosis bronchiectasis (NCFB).
Positive topline results were reported from the Phase 2b study of treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension (PAH), leading to plans for a Phase 3 study.
A Phase 3 study of TPIP in pulmonary hypertension associated with interstitial lung disease (PH-ILD) was initiated in Q4 2025 and is actively enrolling patients.
Enrollment was completed in the Phase 2 CEDAR study for brensocatib in Hidradenitis Suppurativa (HS) in October 2025.
The development program for brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP) was discontinued in December 2025 after the Phase 2b BiRCh study did not meet its primary or secondary efficacy endpoints.
Phase 1 studies for INS1201 in Duchenne Muscular Dystrophy (DMD) and INS1202 in Amyotrophic Lateral Sclerosis (ALS) commenced enrollment.
Global rights to INS1148, an investigational monoclonal antibody, were acquired in December 2025.
The company's stock price increased by over 150% in 2025.
Insmed was ranked as the top company to work for in the biopharma industry in Science's 2025 Top Employers Survey for the fifth consecutive year and certified as a Great Place to Work in the U.S. for the fifth year.
The balance sheet was enhanced through a public equity offering and the redemption of outstanding 0.75% convertible senior notes due in 2028.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing as highly positive, driven by strong revenue growth for ARIKAYCE, successful multi-region approvals and launch of BRINSUPRI, and positive clinical trial results for TPIP, all contributing to a significant stock price increase and top-tier employee recognition. The discontinuation of one program is a minor setback against a backdrop of substantial progress.

Positives

Total Company revenues reached $606.4 million in 2025.
Global ARIKAYCE revenues increased by 19% year-over-year in 2025.
BRINSUPRI received approvals in the U.S. (August 2025), EU (November 2025), and UK (February 2026) for NCFB.
Positive topline results from the Phase 2b study of TPIP in PAH, meeting primary and secondary efficacy endpoints, leading to plans for a Phase 3 study.
Initiated Phase 3 study of TPIP in PH-ILD in Q4 2025.
Completed enrollment in Phase 2 CEDAR study for brensocatib in HS in October 2025.
Commenced enrollment in Phase 1 studies of INS1201 for DMD and INS1202 for ALS.
Acquired global rights to INS1148, an investigational monoclonal antibody, in December 2025.
The company's stock price increased by over 150% in 2025.
Ranked as the top company to work for in the biopharma industry in Science's 2025 Top Employers Survey for the fifth consecutive year.
Certified as a Great Place to Work in the United States for the fifth consecutive year.
Enhanced the balance sheet through a public equity offering and the redemption of 0.75% convertible senior notes due 2028.
2022 Performance-Based Restricted Stock Units (PSUs) vested in February 2025 upon achievement of brensocatib milestones and Insmed's Total Shareholder Return (TSR) ranking in the top decile of the peer group.

Negatives

Discontinued the development program for brensocatib in chronic rhinosinusitis without nasal polyps (CRSsNP) in December 2025 after the Phase 2b BiRCh study did not meet its primary or secondary efficacy endpoints.

Risks

Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, and achievements to differ materially from those discussed, projected, anticipated, or indicated.
The Audit Committee oversees major risk exposures, including financial, legal, regulatory, compliance, and cybersecurity risks.
The Board considers specific risk topics related to the strategic plan, capital structure, R&D activities, manufacturing and supply chain, and operations.
Compensation policies and programs are assessed for their potential to encourage excessive risk-taking.

Future Outlook

The company plans to initiate a Phase 3 study of TPIP in patients with PAH based on positive Phase 2b results and is actively enrolling patients in PALM-ILD, a Phase 3 study of TPIP in PH-ILD. Enrollment continues for Phase 1 studies of INS1201 for DMD and INS1202 for ALS. Preparations are progressing for an sNDA filing for ARIKAYCE in all MAC lung patients, pending anticipated ENCORE data readout. The company also continues to advance its pre-clinical research programs, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Brensocatib remains under review for NCFB by regulatory authorities in Japan.

Management Comments

We are a people-first global biopharmaceutical company striving to deliver firstand best-in-class therapies to transform the lives of patients facing serious diseases.
Our executive compensation program is designed to attract, retain, and incentivize the best possible talent.
The combined Chair and CEO role, balanced with strong shared leadership from the Lead Independent Director, is a strength for the Company.

Industry Context

StockSavvy.ai notes that Insmed's focus on rare diseases and specialty biopharmaceuticals aligns with a growing trend in the industry towards high-unmet-need indications, which often command premium pricing and offer longer market exclusivity. The successful launch of BRINSUPRI and continued growth of ARIKAYCE demonstrate effective commercialization in these niche markets. The expansion of its pipeline into gene therapy and AI-driven protein engineering reflects the broader industry's push towards advanced therapeutic modalities and technological innovation to address complex diseases like DMD and ALS. The discontinuation of the brensocatib CRSsNP program, while a setback, is a common occurrence in R&D-intensive biopharma, indicating a disciplined approach to portfolio management.

Comparison to Industry Standards

Insmed's 19% year-over-year revenue growth for ARIKAYCE in 2025 is strong, especially for an established rare disease product, potentially outperforming many peers in the mature product phase.
The over 150% stock price increase in 2025 significantly outpaced the Nasdaq Biotech Index, which showed a cumulative TSR of 120% over five years (implying a much lower annual growth rate for the index in 2025). This indicates superior shareholder value creation compared to the broader biotech market.
The vesting of 2022 PSUs with Insmed's TSR ranking in the top decile of the peer group (Nasdaq Biotech Index constituents) demonstrates exceptional performance relative to industry benchmarks, rewarding executives for significant shareholder value creation.
The median employee compensation of $284,512 in 2025 is notably high, reflecting the specialized and highly compensated talent pool typical in the biopharmaceutical industry, particularly for a company with successful commercial products and a robust R&D pipeline. This figure would likely be competitive with or exceed median compensation at comparable biopharma companies.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Class II Director	David W.J. McGirr	N/A (not standing for re-election)	May 13, 2026 (Annual Meeting)	Not standing for re-election
Chief Legal Officer	N/A (previously Senior Vice President, General Counsel)	Michael A. Smith	January 2024	Promotion
Chair of the Board of Directors, Xilio Therapeutics, Inc.	N/A	Sara Bonstein	January 2026	Appointment to external board
Board of Directors, Definium Therapeutics, Inc.	N/A	Roger Adsett	January 2026	Appointment to external board

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Structure	Board size designated by resolution, not to exceed 12 directors; currently up to eight directors following the Annual Meeting.	N/A	Ensures flexibility in board composition while maintaining a reasonable size for effective oversight.
Director Independence	7 of 8 directors are independent; all Board committee members are independent.	N/A	Strengthens independent oversight and reduces potential conflicts of interest.
Leadership Structure	Maintains combined Chair and CEO role (William H. Lewis) balanced with a Lead Independent Director (David R. Brennan) with robust responsibilities.	N/A	Provides unified leadership while ensuring independent oversight and accountability.
Board Oversight	Board and Compensation Committee oversee executive officer succession planning; Board oversees sustainability efforts; Audit Committee oversees major risk exposures (financial, legal, regulatory, cybersecurity); Science and Technology Committee oversees R&D and clinical development.	N/A	Enhances strategic planning, risk management, and long-term sustainability focus across key operational areas.
Board Evaluation and Refreshment	Annual self-evaluations for Board and committees, with a third-party facilitator used in 2024; Nominations and Governance Committee addresses Board refreshment and director succession planning.	N/A	Promotes continuous improvement in board effectiveness and ensures a diverse range of expertise and perspectives.
Policy Review	Annual review of committee charters and Corporate Governance Guidelines.	N/A	Ensures governance documents remain current and effective in guiding corporate practices.
Stock Ownership Guidelines	Stock ownership guidelines for directors and executive officers; minimum ownership requirements for executive officers increased in 2025.	November 2025	Further aligns the interests of executives and directors with those of shareholders, encouraging long-term value creation.
Insider Trading Policy	Prohibits hedging, short sales, derivative transactions, and holding Company securities in a margin account; pledging subject to restrictions.	N/A	Mitigates potential for insider trading and promotes ethical conduct regarding company securities.
Director Public Board Limits	Directors limited to four public company boards (including Insmed), public company CEOs limited to two.	N/A	Ensures directors can dedicate sufficient time and attention to their responsibilities at Insmed.
Ethics Reporting	Maintains an ethics hotline for anonymous reporting of violations.	N/A	Fosters a culture of ethical conduct and provides a mechanism for addressing concerns.
Director Resignation Policy	Policy in place for uncontested director elections where votes withheld exceed votes cast for election.	N/A	Enhances accountability of directors to shareholders in uncontested elections.
Executive Compensation Advisory Vote	Annual shareholder advisory vote on executive compensation.	N/A	Provides shareholders with a voice on executive compensation practices and promotes transparency.
Capital Structure	No dual-class stock.	N/A	Ensures equal voting rights for all common shareholders.
Compensation Recoupment Policy	Maintains a compensation recoupment policy with provisions beyond Dodd-Frank and Nasdaq requirements, covering excess compensation in restatement events and fraud/intentional misconduct.	N/A	Strengthens accountability for executive compensation and protects shareholder interests in cases of misconduct or financial restatement.

Related Party Transactions

Since January 1, 2025, there were no related party transactions, nor are there currently any proposed related party transactions, which would require disclosure in this Proxy Statement.

Stakeholder Impact

Patients: The company's mission is to 'transform patients lives' through firstand best-in-class therapies. Product approvals (BRINSUPRI) and clinical trial advancements (TPIP, INS1201, INS1202) directly benefit patients with serious diseases.
Employees: Recognized as a top biopharma employer for the fifth consecutive year and a Great Place to Work, with increased focus on development plans, a new mentorship program, and enhanced compensation programs designed for attraction, retention, and engagement.
Shareholders: Experienced a stock price increase of over 150% in 2025, indicating significant shareholder value creation. Executive compensation is aligned with shareholder interests through equity awards and performance-based incentives. The public equity offering and debt redemption further strengthened the balance sheet.
Communities: The Board oversees sustainability efforts and initiatives, and the company published its third Responsibility Report in 2025, demonstrating a commitment to broader societal impact.

Next Steps

Elect two Class II directors at the Annual Meeting on May 13, 2026.
Conduct an advisory vote on the 2025 compensation of named executive officers at the Annual Meeting.
Ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2026.
Initiate a Phase 3 study of TPIP in patients with PAH.
Continue actively enrolling patients in PALM-ILD, a Phase 3 study of TPIP in PH-ILD.
Continue enrolling patients in Phase 1 studies of INS1201 for DMD and INS1202 for ALS.
Progress preparation for sNDA filing for ARIKAYCE in all MAC lung patients in advance of anticipated ENCORE data readout.
Continue advancing pre-clinical research programs.

Key Dates

Date	Description
2001-05-01	Melvin Sharoky, M.D. became a Director.
2012-09-01	William H. Lewis became CEO.
2018-11-01	William H. Lewis became Chair of the Board; David R. Brennan became Lead Independent Director; Elizabeth McKee Anderson became a Director.
2019-11-01	Clarissa Desjardins, Ph.D. became a Director.
2020-01-01	Sara Bonstein became Chief Financial Officer.
2020-04-01	Carol A. Schafer became a Director.
2022-01-01	Select senior leaders, including NEOs, received an award of Performance-Based Restricted Stock Units (PSUs).
2024-01-01	Michael A. Smith was promoted to Chief Legal Officer.
2024-08-01	Compensation Committee approved a new compensation peer group.
2025-02-01	2022 Performance-Based Restricted Stock Units (PSUs) vested upon achievement of performance and service conditions.
2025-08-01	BRINSUPRI approved in the U.S.
2025-09-04	JPMorgan Chase & Co. filed Schedule 13G/A.
2025-09-30	Darwin Global Management, Ltd. beneficial ownership date.
2025-10-01	Completed enrollment in Phase 2 CEDAR study.
2025-11-01	BRINSUPRI approved in the EU; Stock ownership guidelines updated.
2025-11-14	Darwin Global Management, Ltd. filed Schedule 13G/A.
2025-12-01	Completed Phase 2b BiRCh study; Discontinued brensocatib development in CRSsNP; Acquired global rights to INS1148; Awarded incremental grant of PSUs to senior leaders and research personnel.
2025-12-31	Fiscal year end for Annual Report on Form 10-K; BlackRock, Inc. beneficial ownership date; Employee population count for pay ratio.
2026-01-01	Sara Bonstein became Chair of Xilio's board of directors; Roger Adsett joined Definium Therapeutics, Inc. board.
2026-01-08	The Vanguard Group filed Schedule 13G/A.
2026-01-21	BlackRock, Inc. filed Schedule 13G/A.
2026-02-01	BRINSUPRI approved in the UK.
2026-03-06	Record Date for the Annual Meeting.
2026-04-01	Proxy Statement first furnished to shareholders.
2026-05-12	Deadline for internet/telephone proxy voting.
2026-05-13	Annual Meeting of Shareholders.
2026-12-02	Deadline for shareholder proposals for inclusion in the 2027 Annual Meeting proxy statement.
2026-12-15	Earliest date for shareholder nominations for directors or other business for the 2027 Annual Meeting.
2027-01-14	Latest date for shareholder nominations for directors or other business for the 2027 Annual Meeting.
2027-05-13	Term of Class III directors will expire at the 2027 Annual Meeting of Shareholders.
2028-05-13	Term of Class I directors will expire at the 2028 Annual Meeting of Shareholders.
2028-12-31	End of three-year period for IND application acceptances for 2025 PSUs performance condition.
2029-02-01	Vesting date for 2025 PSUs (subject to continuous employment).
2029-05-13	Term of office for elected Class II directors will expire at the 2029 Annual Meeting of Shareholders.

Recommendation

strong buy

The filing reveals robust operational and strategic execution, marked by significant revenue growth for ARIKAYCE, successful multi-regional approvals and launch of BRINSUPRI, and promising clinical advancements for TPIP. The substantial stock price appreciation of over 150% in 2025, coupled with executive compensation tied to top-decile TSR performance, indicates strong shareholder value creation. While one program was discontinued, the overall pipeline progress, strategic acquisitions, and strong corporate governance practices suggest continued positive momentum and a compelling investment opportunity.

Keywords

Insmed, ARIKAYCE, BRINSUPRI, Brensocatib, NTM lung disease, MAC lung disease, Non-cystic fibrosis bronchiectasis, NCFB, TPIP, Pulmonary Arterial Hypertension, PAH, Pulmonary Hypertension associated with Interstitial Lung Disease, PH-ILD, Hidradenitis Suppurativa, HS, Duchenne Muscular Dystrophy, DMD, Amyotrophic Lateral Sclerosis, ALS, Gene therapy, Biopharmaceutical, SEC filing, Proxy statement, Executive compensation, Corporate governance, Clinical trials, Drug development, Rare diseases

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.